Cariprazine: adverse event reports filed with FDA

795

reports as suspect product

0% of all reports · about 77 a year

177

reports, 12 months to June 2026

196 in the 12 months before

84%

marked serious by the reporter

70.7% across the class

6.3%

record death among outcomes, as reported

50 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Cariprazine reports recording the termmedian drug in atypical antipsychotic

1. Drug ineffectivethe medicine did not work as expected15%119
2. Drug interactionan interaction between medicines14.1%112
3. Weight increasedweight gain8.8%70
4. Akathisiainner restlessness and an urge to move8.2%65
5. Suicidal ideationthoughts of suicide7.8%62
6. Parkinsonism6.4%51
7. Extrapyramidal disordermovement problems such as stiffness or tremor6%48
8. Product use in unapproved indicationused for a purpose not on the label5.9%47
9. Insomniadifficulty sleeping5.8%46
10. Off label useused for a purpose or in a way not on the label5.7%45
11. Treatment noncompliancethe treatment was not taken as directed5.5%44
12. Hallucination, auditory5.3%42
13. Intentional overdosea deliberate overdose5.2%41
14. Tremorshaking4.9%39
15. Completed suicidedeath by suicide4.5%36
16. Fatiguetiredness4.4%35
17. Anxietyanxiety4.3%34
18. Sedationdrowsiness from a medicine4.3%34
19. Serotonin syndrometoo much serotonin activity, with agitation, fever and tremor4.2%33
20. Delusiona fixed false belief4%32
21. Overdosea dose above the recommended amount4%32
22. Somnolencedrowsiness3.9%31
23. Suicide attempta suicide attempt3.8%30
24. Orthostatic hypotension3.6%29
25. Condition aggravatedthe condition being treated got worse3.5%28
26. Dizzinesslight-headedness or unsteadiness3.1%25
27. Drug resistance3%24
28. Brain fog2.9%23
29. Distributive shock2.9%23
30. Therapeutic product effect incomplete2.9%23

Top 30 of 311 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 37 drugs in the atypical antipsychotic class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 683,680 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 31.4% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 795 reports.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the atypical antipsychotic class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Cariprazine as a suspect or interacting product; reports listing it only as a concomitant medication (306) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.